FDA Issues Advice on Limited Population Pathway for Antimicrobials

International Pharmaceutical Regulatory Monitor
A A
The FDA released draft guidance for sponsors who want to use the agency’s limited population pathway for antibacterial and antifungal drugs.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor